Lead Product(s) : Foliglurax
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lundbeck reports headline results from phase IIa AMBLED study of foliglurax in Parkinson’s disease
Details : The phase IIa study of Lundbeck's selective positive allosteric modulator of the glutamate 4 receptor, foliglurax, for the treatment of Parkinson's disease did not meet the primary study endpoint.
Product Name : PXT 002331
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2020
Lead Product(s) : Foliglurax
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable